These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 25929192

  • 1. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 2. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    BMC Musculoskelet Disord; 2018 Jul 03; 19(1):210. PubMed ID: 29970059
    [Abstract] [Full Text] [Related]

  • 3. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug 03; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
    Kim KJ, Min YK, Koh JM, Chung YS, Kim KM, Byun DW, Kim IJ, Kim M, Kim SS, Min KW, Han KO, Park HM, Shin CS, Choi SH, Park JS, Chung DJ, Mok JO, Baek HS, Moon SH, Kim YS, Lim SK, VALUE study group.
    Yonsei Med J; 2014 May 03; 55(3):715-24. PubMed ID: 24719139
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH, Binkley N, Boonen S, Kiel DP, Reginster JY, Roux C, Chen L, Rosenberg E, Santora A, FOCUS-D (FOSAVANCE vs. Standard Care-Use and Study of Vitamin D) Trial.
    Calcif Tissue Int; 2011 Jun 03; 88(6):485-94. PubMed ID: 21479913
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 03; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 7. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
    Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC.
    Bone; 2009 Apr 03; 44(4):639-47. PubMed ID: 19185560
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb 03; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 9. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar 03; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 10. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Baek K, Mok J, Kim D, Kim D, Kim H, Kim Y, Myoung S, Kim D, Lim SK.
    Osteoporos Int; 2006 Dec 03; 17(12):1801-7. PubMed ID: 17019520
    [Abstract] [Full Text] [Related]

  • 11. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan 03; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 12. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.
    Curr Med Res Opin; 2006 Sep 03; 22(9):1745-55. PubMed ID: 16968578
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.
    Osteoporos Int; 2014 Apr 03; 25(4):1401-10. PubMed ID: 24510095
    [Abstract] [Full Text] [Related]

  • 15. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 03; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 16. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec 03; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 17. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
    Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A.
    Osteoporos Int; 2015 Apr 03; 26(4):1295-302. PubMed ID: 25524023
    [Abstract] [Full Text] [Related]

  • 18. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec 03; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 19. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
    Shapses SA, Kendler DL, Robson R, Hansen KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM, Santora AC.
    J Bone Miner Res; 2011 Aug 03; 26(8):1836-44. PubMed ID: 21448918
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.
    Bosn J Basic Med Sci; 2011 Feb 03; 11(1):41-5. PubMed ID: 21342141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.